Navigation Links
Gamma interferon a wake-up call for stem cell response to infection

HOUSTON -- (June 10, 2010) Most of the time, the body's blood-forming (hematopoietic) stem cells remain dormant, with just a few producing blood cells and maintaining a balance among the different types.

However, invading bacteria can be a call-to-arms, awaking the sleeping stem cells and prompting them to produce immune system cells that fight the foreign organisms. The "bugler" that awakes the stem cells in this battle is gamma interferon, a front-line protein defender against bacterial infection, said researchers from Baylor College of Medicine ( in a report that appears in the current issue of the journal Nature (

"We are looking at the normal function of stem cells," said Dr. Margaret Goodell (, professor of molecular and human genetics at BCM and director of the Stem Cells and Regenerative Medicine (STaR) ( Center. She is the report's senior author. "One of those is to respond to an infection."

Goodell and her colleagues knew that cells farther along in the differentiation process responded to infection, increasing the production of immune cells.

"We were sure there was a mechanism by which hematopoietic stem cells respond to infection, but it was not obvious," she said. They started their work with gamma interferon because they knew it played an important role in bacterial infection.

The collaboration and talents of two researchers in her laboratory first co-authors Drs. Megan T. Baldridge and Katherine Y. King facilitated the work with mice that led to this finding, said Goodell. Both are at BCM.

"I think our findings represent an exciting new avenue for studying hematopoiesis," said King. "By viewing the hematopoietic stem cell as the source of the immune system, we are finding fundamental ways in which the immune response affects bone marrow. This is the first time that anyone has extensively studied hematopoietic stem cells in the context of an in vivo model (a living organism) of infection."

"As a specialist in infectious diseases, I see many patients whose bone marrow no longer produces sufficient blood cells as a consequence of their infection. This is particularly relevant in chronic infections such as mycobacterial diseases (that include tuberculosis) and AIDS," said King. "Our studies lend insight into the causes of this decrease in bone marrow function during such infections, and I hope the work will someday lead to new therapies."

Studies in mice with a chronic or long-term infection called Mycobacterium avium show that a greater proportion of a particular subset of their cells called long-term hematopoietic (blood-forming) stem cells are active. Gamma interferon prompts this activity. Mice that lack gamma interferon have fewer of these stem cells active during infection.

These findings show that gamma interferon not only activates stem cells during infection, but also regulate stem cells in normal times, enabling them to maintain the types of blood cells that exist in proportion or homeostasis.

"Our model predicts that bacterial infection detected by sentinel immune cells stimulates the increased release of gamma interferon, which then travels through the blood stream to activate HSCs (hematopoietic stem cells) in the bone marrow, leading to expansion and mobilization of the immune progenitor pool (the cells that ultimately produce immune system cells)," the researchers wrote.

They found that sustained activity by the hematopoietic stem cells can lead to at least transient problems with the quality of the stem cells and their abilities to stimulate production of more immune system cells.

"One of the most important things we found is the chronic infections (such as tuberculosis or HIV/AIDS) may be lead to bone marrow exhaustion," said Baldridge. "We knew that a condition called anemia of chronic disease exists, and this could be one of the contributing factors."


Contact: Glenna Picton
Baylor College of Medicine

Related biology news :

1. Gamma interferon could aid fight against fungal infections
2. Gamma globulin effective in treating eye infections caused by adenoviruses
3. The right response to every pathogen
4. Bacterioplankton responses to desert dust in the (sub)tropical northeast Atlantic
5. Receptor variant influences dopamine response to alcohol
6. Cheese found to improve the immune response of the elderly
7. NASA deploys planes, targets satellites to aid in oil spill response
8. Study links 1976 swine flu shot to stronger immune response to 21st century pandemic flu
9. Chronix Biomedicals serum DNA assays monitor disease activity and treatment response in MS
10. Rapid response team investigates coral disease outbreak in Kaneohe Bay, Oahu
11. Discovery that PARP protein exists in all breast tumors will help target chemo and predict response
Post Your Comments:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology: